$CURR: The upcoming Q4 financial report is project
Post# of 40253
(Total Views: 150)
Posted On: 01/03/2023 11:23:55 AM
$CURR: The upcoming Q4 financial report is projected to deliver continued revenue growth and improvements based on the successful marketing of the company's wellness and anging product lines.
https://finance.yahoo.com/news/cure-pharmaceu...00414.html
From the Q3 results:
*Revenue in the third quarter surged 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million with further increases expected in Q4.
*Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.
*SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.
*Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.
https://finance.yahoo.com/news/cure-pharmaceu...00414.html
From the Q3 results:
*Revenue in the third quarter surged 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million with further increases expected in Q4.
*Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.
*SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.
*Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.
(0)
(0)Scroll down for more posts ▼